去纤苷国内去哪里买？

Hepatic veno-occlusive disease (HVOD) is one of the serious complications after hematopoietic stem cell transplantation (HSCT), and the mortality rate in patients with severe HVOD can be as high as 100%. It is a mixture of single-stranded oligonucleotides with anti-thrombotic and fibrinolytic effects. In recent years, multiple clinical research results have shown that defibrotide is a safe and effective drug for preventing and treating HVOD after HSCT. Defibrotide was first developed by Gentium Pharmaceuticals in Italy and was approved for marketing in the EU in October 2013. After Gentium Pharmaceuticals was acquired by Jazz Pharmaceuticals of the United States, defibrotide was approved by the U.S. Food and Drug Administration (FDA) for marketing in the United States on March 30, 2016, under the trade name Defitelio.

In vitro, defibrinated sodium enhances the enzymatic activity of plasmin that hydrolyzes fibrin clots. Studies evaluating the pharmacological effects of defibrinated sodium on endothelial cells (ECs) have been primarily conducted in human microvascular endothelial cell lines. In vitro, defibrotide increases tissue plasminogen activator (t-PA) and thrombomodulin expression and decreases von Willebrand factor (vWF) and plasminogen activator inhibitor-1 (PAI-1) expression, thereby reducing EC activation and increasing EC-mediated fibrinolysis. Defibrinated sodium protects ECs from chemotherapy, tumor necrosis factor-alpha (TNF-alpha), serum starvation, and perfusion-induced injury.

In clinical trials, heparin was used to prevent diseases such as hepatic veno-occlusion while greatly increasing the risk of bleeding, while defibrinoside alone or in combination with heparin had a very low incidence of side effects and achieved good results in preventing HVOD. In a phase III multi-center randomized clinical trial completed in Europe, a total of 356 stem cell transplant patients were recruited. The incidence of hepatic vein occlusion 30 days after transplantation was compared. It was found that 2 of 180 patients in the defibrotide group developed hepatic vein occlusion, accounting for 12%; 35 of 176 patients in the control group developed hepatic vein occlusion, accounting for 20%.

So the question is, where can I buy defibrinoside in China? I regret to tell you that defibrotide is not available on the domestic market, so it cannot be purchased domestically. Patients who need the drug can obtain authentic products listed overseas through domestic professional overseas medical service organizations, such as Medical Companion Travel.